No abstract available.
Growth Hormone* ; Thyroid Gland*

No abstract available.
Gene Expression* ; Humans* ; Insulin-Like Growth Factor I* ; Thyroid Gland*

Following irradiation with 2.45GHz microwave, pituitary hormonal changes in rabbits were observed. A 30 rabbits (New Zealand, White, Male) were used for the experiments, 10 for each experiment immediately following one two and four weeks after irradiation with amount of 2.4 Joule/cm2, 4.8 Joule/cm2 and 7.2 Joule/cm2 respectively. The following are the results of the study as a conclusion. The secretion of cortisol hormone increased immediately after the exposure and then decrease to below that of the control group until two weeks afterwards, followed by recovery phase with secretion level approaching that of the central group in 4 weeks. Lutenizing hormone showed a tendency of increase from the first week of exposure, rather than immediately after, lasting up to over four weeks, In the irradiation group for 30 min, however, the increase began immediately after the exposure. The secretion of of growth hormone showed an insignificant, increase after the second and fourth weeks over the control group. The duration of exposure did not have much effect on the hormonal secretion. Thyroid stimulating hormone showed a different pattern changes: increase of immediately after exposure, decreased in two weeks, and then approaching the level of the control group after four weeks.
Growth Hormone* ; Hydrocortisone ; Microwaves* ; Pituitary Hormones ; Rabbits* ; Thyroid Gland* ; Thyrotropin

PURPOSE: Papillary thyroid carcinomas are hypervascular tumors. The tumor growth and their metastases are dependent on factors that stimulate vessel formation (angiogenesis). Vascular endothelial growth factor (VEGF) has been reported to play an important role in the angiogenesis in papillary thyroid carcinomas in terms of the clinicopathological prognostic factors. METHODS: The expression of VEGF in specimens surgically removed from 23 papillary thyroid cancer patients were examined by immunohistochemical methods. RESULTS: The rate of VEGF expression was 56.5% in the tumor cells. The degree of VEGF expression was significantly correlated with local lymph node metastases (P=0.029) and the tumor extent (P=0.036). However, the degree of VEGF expression did not correlate with any clinicopathological characteristics. CONCLUSION: VEGF expression can be a useful prognostic factor of papillary thyroid carcinomas.
Humans ; Lymph Nodes ; Neoplasm Metastasis ; Thyroid Gland* ; Thyroid Neoplasms* ; Vascular Endothelial Growth Factor A*

We made a clinical observation of 17 cases of congenital Hypothyroidism at the Pediatric department of Yonsei University hospital in Seoul, Korea during the period from January, 1969 to August, 1979. The results were as followings : 1) Male to female sex was about 1 : 1.1, and 6 cases (35%) of congenital hypothyroid-sm were diagnosed under 1 year old. 2) In etiological classificattion, aplastic or hypoplastic glands was 7 cases (41.2%) and normal or enlarged gland, 6 cases (35.3%) and ectopic thyroid tissue, 4 cases (23.5%). 3) In all cases, height and bone age retarded below normal range. 4) All cases were improved slightly after receiving dessicated thyroid and sodium-1 thyroxin therapy. Three cases had regalned normal growth and development after 6 months of treatment.
Congenital Hypothyroidism* ; Female ; Growth and Development ; Humans ; Korea ; Male ; Reference Values ; Seoul ; Thyroid Dysgenesis ; Thyroid Gland ; Thyroxine

Background:Eutropin is a recombinant human growth hormone preparation and has been used in patients with growth hormone deficiency. Short stature is a characteristic feature of Turner syndrome, which is caused by sexual chromosomal anomalies. Growth hormone therapy would increase growth velocity and increase the ultimate final height in patients with Turner syndrome. The purpose of this study was to evaluate the clinical effects and safety in patients with Turner syndrome with Eutropin treatment. Subjects and METHODS:60 patients with Turner syndrome,who were diagnosed by chromosome study,were treated with Eutropin 1IU/kg/week for 12 months and followed up every 3 month. The height and weight were evaluate at 0, 3, 6, 9, 12 months. A complete blood count, ESR, urinary analysis and chemistry studies were done every 3 month. IGF- I , T4, TSH & anti-GH antibody were measured at 6 months and 12 months. Chest X-ray was checked at 0, 6 ,12 months. RESULTS:60 patients were enrolled but 10 patients were lost or treated irregularly and excluded in the study of growth effect. but included all cases in safety analysis. At the onset of Eutropin therapy,their mean age was 10.8+/-2.9 years old(range 4.2- 14.9yr)and the height was 121.1+/-13.7cm(-3.1+/-0.9 SDS) and yearly growth velociy was 3.4+/-1.5cm. Their weight was 30.5+/-10.6kg and bone age 9.1+/-3.0 yrs. After Eutropin treatment, mean height was increased to 123.2+/-13.5cm at 3 months, 125.2+/-13.1cm at 6 months, 127.5+/-12.4cm at 9 months, 128.3+/-12.8cm at 12 months. Height velocity were increased to 8.3+/-3.1cm at 3 months, 8.1+/-2.6cm at 6 months, 7.6+/-1.9cm at 9 months and 7.1+/-1.9cm at 12 months(P<0.001). Height SDS at 0, 3, 6, 9, 12 months were -3.1+/-0.9, -2.9+/-1.0, -2.7+/-0.9, -2.7+/-0.9 respectively(P>0.001).Their bone age were 9.1+/-3.0yr, 9.6+/-2.9yr, 10.2+/-2.7yr before and 6 & 12 months after treatment respectively. HA/BA were 0.84+/-0.15, 0.87+/-0.13, 0.88+/-0.12 at before and 6 & 12 months after treatment respectively(P<0.05). Growth velocity of 4-8 yrs group was most prominent compared to other groups. Serum IGF- I concentration was increased from 167.4+/-85.8ng/ml to 368.4+/-158.1ng/ml at 6 months and 423.2+/-181.0ng/ml at 12 month(P<0.001) after treatment. No significant changes were observed in thyroid function, CBC, ESR, Blood chemistry and urinalysis. Anti-hGH antibody were positive in 2 patients, but these didnot attenualte the growth velocity. CONCLUSION: Treatment with Eutropin increased significantly height velocity in patients with Turner syndrome. No specific adverse events were observed during Eutropin therapy.
Blood Cell Count ; Chemistry ; Growth Hormone ; Human Growth Hormone ; Humans* ; Thorax ; Thyroid Gland ; Turner Syndrome* ; Urinalysis

Thyroid hormones play an important role in normal growth and development throughout infancy, childhood, and adolescence. Abnormalities of thyroid function during the fetal period and infancy result in impaired development of the brain and skeleton. In childhood and adolescence, thyroid disorders can negatively affect normal growth and pubertal development. Therefore, early diagnosis and treatment of thyroid disorders are essential for obtaining excellent outcomes. Because most pediatric patients with thyroid disorders need long-term therapy, and can experience adverse effects or have an unfavorable prognosis, physicians should provide professional treatment and monitoring.
Adolescent ; Brain ; Early Diagnosis ; Growth and Development ; Humans ; Hyperthyroidism ; Hypothyroidism ; Prognosis ; Skeleton ; Thyroid Gland ; Thyroid Hormones ; Thyroid Neoplasms

Patients with acromegaly have high incidence of benign or malignant neoplasia than general population and many investigators suggest the stimulatory effect of GH and IGF-1 on mesenchymal cells. Both normal thyroid tissue and thyroid cancer cells express IGF-1 receptor and thyroid cancer cells have more than 3 times. We present a case of acromegaly in patient with mixed papillary-follicular thyroid carcinoma, suggesting the possible carcinogenic role of GH and IGF-1.
Acromegaly* ; Humans ; Incidence ; Insulin-Like Growth Factor I ; Receptor, IGF Type 1 ; Research Personnel ; Thyroid Gland* ; Thyroid Neoplasms*

PURPOSE: Thyroid hormone is essential for normal growth and development. The aim of this study was to evaluate the factors affecting final adult height in patients with congenital hypothyroidism. METHODS: The study group was comprised of 42 patients who were diagnosed as congenital hypothyroidism and attained final adult height. Retrospectively, we reviewed medical records as to clinical and laboratory data. We analyzed the influence of various factors on final adult height(FAH) in patients with congenital hypothyroidism. RESULTS: The mean chronologic age at initiation of treatment was 5.85+/-4.32 years and the FAH deviation score(SDS) was -1.21+/-1.14. The age at initiation of treatment, the chronologic age, the mean dose of L-thyroxine of current treatment, and the bone age delay at initiation of treatment were negatively related to the FAH SDS(P<0.05). The height SDS at initiation of treatment and the height SDS at initiation of puberty were positively related to the FAH SDS(P<0.05). Analyzing according to etiology, the FAH SDS of dyshormonogenesis, thyroid aplasia, thyroid ectopia, and thyroid hypoplasia were 0.16+/-0.27, -1.15+/-0.97, -1.45+/-1.07, and -2.70+/-1.70 respectively(P<0.05). CONCLUSION: The younger the age at initiation of treatment and the chronologic age, and the more the mean dose of L-thyroxine of current treatment and the bone age delay at initiation of treatment, The higher the final adult height SDS. The higher the height SDS at initiation of treatment and the height SDS at initiation of puberty, the final adult height SDS were the higher.
Adolescent ; Adult* ; Congenital Hypothyroidism* ; Growth and Development ; Humans ; Medical Records ; Puberty ; Retrospective Studies ; Thyroid Dysgenesis ; Thyroid Gland ; Thyroxine

PURPOSE: Papillary Thyroid Microcarcinoma (PTMC) is rapidly increasing due to increased interests in the public health care system and improvements in ultrasonographic instruments and fine-needle-aspiration technique. The aim of this study is to investigate relationships between clinicopathologic features and molecular markers of PTMC and to help in developing therapeutic strategies in PTMC. METHODS: Tissue samples from patients with 38 PTMC and 21 benign thyroid tumors that were operated on from Jan. 2006 to Nov. 2008 were used to make microarrays and immunohistochemical staining for ER-alpha, E-CD, VEGF, MMP-2, MMP-9, and HIF-1alpha were performed. Clinicopathologic features of each immunohistochemical staining group were analyzed retrospectively. RESULTS: There is no immunohistochemistry staining in cases with benign thyroid lesions. The expression rate of ER-alpha, E-CD, VEGF, MMP-2, MMP-9, and HIF-1alpha in PTMC group was 66%, 58%, 82%, 66%, 71% and 63%, respectively. Bilateral tumor was statistically significant (48.0% vs 7.7%, P=0.015) related to MMP-2(+) PTMC group than in MMP-2(-) group. Bilateral tumor (44.4% vs 9.1%, P=0.060) and lymphovascular invasion (25.9% vs 0%, P=0.084) seemed to have greater relation to MMP-9(+) PTMC group than to MMP-9(-) group, but there is no statistically significant difference. Bilateral tumor (50.0% vs 7.1%, P=0.012), lymph node metastasis (45.8% vs 0%, P=0.003) and lymphovascular invasion (29.2% vs 0%, P=0.033) were significantly related to HIF-1alpha (+) PTMC group compared to HIF-1alpha(-) group. CONCLUSION: Our findings suggest that MMP-2, MMP-9 and HIF-1alpha expression could be used as a prognostic marker in PTMC. Larger studies are needed to assess its prognostic value in PTMC.
Carcinoma, Papillary ; Humans ; Immunohistochemistry ; Lymph Nodes ; Neoplasm Metastasis ; Public Health ; Thyroid Gland ; Thyroid Neoplasms ; Vascular Endothelial Growth Factor A